Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY-AID: Early ED Sublingual Edaravone Dexborneol in AIS Reperfusion
ChiCTR2600117665Phase 4Not yet recruiting
- Sponsor
- Zigong Fourth People's Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ischemic stroke comparing Reperfusion therapy + sublingual edaravone dexborneol with Reperfusion therapy + placebo (2 arms). Primary endpoint: Proportion of patients with mRS score ≤1 at 90 days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600117665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117665.